ReviewCureus2020
How Serotonin Level Fluctuation Affects the Effectiveness of Treatment in Irritable Bowel Syndrome.
Review in Cureus, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 34 citations in OpenAlex.
- Acacia fiber or probiotic supplements to relieve gastrointestinal complaints in patients with constipation-predominant IBS: a 4-week randomized double-blinded placebo-controlled intervention trial.European journal of nutrition · 2024Trial
- A randomized, double-blinded, placebo-controlled clinical trial on Lactobacillus-containing cultured milk drink as adjuvant therapy for depression in irritable bowel syndrome.Scientific reports · 2024Trial
- Bioavailability of Oral Ondansetron in Dogs: A Crossover Study.Journal of veterinary pharmacology and therapeutics · 2026Article
- Article
- Measuring serotonin binding to its receptorsbioRxiv : the preprint server for biology · 2025Article
- Measuring Serotonin Binding to Its Receptors In Vitro via Charge Transfer to ANAP.International journal of molecular sciences · 2025Article
- Abdominal Migraine in Adults: A Narrative Review.Cureus · 2025Review
- Toxoplasma gondii chronic infection decreases visceral nociception through peripheral opioid receptor signaling.PLoS pathogens · 2025Article
- Measurement of Real-Time Serotonin Dynamics from Human-Derived Gut Organoids.Analytical chemistry · 2025Article
- Complex Probiotics Ameliorate Fecal Microbiota Transplantation-Induced IBS in Mice via Gut Microbiota and Metabolite Modulation.Nutrients · 2025Article
- Parasite-mediated alteration of behaviour and biomolecular dynamics in a mouse model.Frontiers in cellular and infection microbiology · 2025Article
- The Latest Data Concerning the Etiology and Pathogenesis of Irritable Bowel Syndrome.Journal of clinical medicine · 2024Review
- Investigating the influence of perinatal fluoxetine exposure on murine gut microbial communities during pregnancy and lactation.Scientific reports · 2024Article
- Gut microbial β-glucuronidases influence endobiotic homeostasis and are modulated by diverse therapeutics.Cell host & microbe · 2024Article
- Pleasurable and problematic receptive anal intercourse and diseases of the colon, rectum and anus.Nature reviews. Gastroenterology & hepatology · 2024Review
- Polycystic Ovary Syndrome and Irritable Bowel Syndrome: Is There a Common Pathway?Endocrinology, diabetes & metabolism · 2024Review
- Mirtazapine for gastrointestinal and neuropsychological symptoms in older adults with irritable bowel syndrome.Therapeutic advances in gastroenterology · 2024Review
- Variety of Serotonin Levels in Pediatric Gastrointestinal Disorders.Diagnostics (Basel, Switzerland) · 2023Article
- Ethanol Extract of Mao Jian Green Tea Attenuates Gastrointestinal Symptoms in a Rat Model of Irritable Bowel Syndrome with Constipation via the 5-hydroxytryptamine Signaling Pathway.Foods (Basel, Switzerland) · 2023Article
- A multi-omic brain gut microbiome signature differs between IBS subjects with different bowel habits.Neuropharmacology · 2023Review
Corrections and comments
- Erratum issued
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Irritable bowel syndrome (IBS) is one of the most commonly diagnosed functional gastrointestinal (GI) disorders. It affects both men and women. Enteric serotonin (5HT) is responsible for gut motility, secretion, visceral hypersensitivity, and inflammation. The serotonin reuptake transporter (SERT) maintains serotonin levels by regulating its reuptake. An increase in SERT expression causes a decrease in serotonin, which leads to IBS-C (irritable bowel syndrome, constipation-predominant), whereas a decrease in SERT transcription causes an increase in serotonin, which leads to IBS-D (irritable bowel syndrome, diarrhea-predominant). Some factors can alter SERT transcription, such as certain bacteria, inflammation, growth factor, and glucagon-like peptide-1. This shows that 5HT and SERT both have an important role in IBS pathophysiology so that it would be a better subject to target for the treatment aspect of IBS. 5HT3 receptor antagonists are advisable for IBS-D to block the excessive activity of serotonin at the 5HT3 receptor and reduce gut motility. For IBS-C, we prescribe 5HT4 receptor agonists, which promote gut motility. Also, the latest treatment approach, antidepressant drugs TCAs (tricyclic antidepressants) and SSRIs (selective serotonin reuptake inhibitors), are helpful by modulating serotonin levels in the gut. In this literature review, we found that serotonin is one of the main pathophysiological factors for IBS, and we can treat IBS by targeting serotonin function on gut motility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.